There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to [...]
Malecare launches Cancergraph, a Quality of Life mobile app recording. It's free on the iOS Apple App store, right now! Go to the App store on your iPhone or Download here https://itunes.apple.com/us/app/cancergraph/id1114343314?mt=8 Android coming in November. Cancergraph tracks your cancer symptoms and side effects over days, months and years. Designed by cancer survivors and caregivers, [...]
Chemotherapy with Taxotere (docetaxel) might not be considered because the side effects are misunderstood. Individual experiences and side effects differ widely from one man to another. n Generally, chemotherapy is not as toxic as we think. Even if a patient feels that his chemotherapy is causing more grief than relief, it can be discontinued; there [...]
We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM [...]
Malecare's Founder and Executive Director Darryl Mitteldorf was this years PCRI winner of the Harry Pinchot Award. He is long deserving of this award. I would like to thank Darryl for his years and years of work and PCRI for recognizing his major contributions to our prostate cancer community. Thank you Darryl A video of [...]